Skip to main content
Clinical and Translational Medicine
Figure 2 | Clinical and Translational Medicine

Figure 2

From: Network insights on oxaliplatin anti-cancer mechanisms

Figure 2

A comparison of cisplatin and oxaliplatin IG50 results on a standard NCI drug screen panel. Adapted from Oxaliplatin, Tetraplatin, Cisplatin, and Carboplatin: Spectrum of Activity in Drug-Resistant Cell Lines and in the Cell Lines of the National Cancer Institute's Anticancer Drug Screen Panel, Rixe et al. 1996 from the journal Biochemical Pharmacology (OpenAccess, which allows unrestricted use of the figures).

Back to article page